Sherry Adkins
Overview
Explore the profile of Sherry Adkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Neelapu S, Adkins S, Ansell S, Brody J, Cairo M, Friedberg J, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33361336
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into...
12.
Strati P, Nastoupil L, Westin J, Fayad L, Ahmed S, Fowler N, et al.
Blood Adv
. 2020 Aug;
4(16):3943-3951.
PMID: 32822484
Neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common acute toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, there are limited data on the clinical...
13.
Strati P, Varma A, Adkins S, Nastoupil L, Westin J, Hagemeister F, et al.
Haematologica
. 2020 Aug;
106(10):2667-2672.
PMID: 32732355
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed...
14.
Sievers S, Watson G, Johncy S, Adkins S
Front Oncol
. 2020 Jul;
10:885.
PMID: 32670871
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy...
15.
Pinnix C, Gunther J, Dabaja B, Strati P, Fang P, Hawkins M, et al.
Blood Adv
. 2020 Jun;
4(13):2871-2883.
PMID: 32589728
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic...
16.
Strati P, Nastoupil L, Fayad L, Samaniego F, Adkins S, Neelapu S
Blood
. 2019 May;
133(26):2800-2802.
PMID: 31101626
No abstract available.
17.
Buitrago J, Adkins S, Hawkins M, Iyamu K, Oort T
Clin J Oncol Nurs
. 2019 Mar;
23(2):42-48.
PMID: 30880816
Background: Significant improvement in overall survival observed in patients on clinical trials and U.S. Food and Drug Administration approval of two chimeric antigen receptor (CAR) T-cell therapies have resulted in...
18.
Neelapu S, Tummala S, Kebriaei P, Wierda W, Locke F, Lin Y, et al.
Nat Rev Clin Oncol
. 2018 Feb;
15(4):218.
PMID: 29434334
No abstract available.
19.
Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F, et al.
Nat Rev Clin Oncol
. 2017 Sep;
15(1):47-62.
PMID: 28925994
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce...
20.
Whittaker S, Adkins S, Phillips R, Jones J, Horsley M, Kelley G
J Telemed Telecare
. 2004 Apr;
10(2):84-8.
PMID: 15068643
We studied a telediabetes programme that had been in operation for 10 years, to identify the factors in its sustainability. We reviewed archive documents, conducted interviews with programme administrators and...